B+
Bull case
20%
Probability
Target price
$117.00
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
MLAB
Mesa LaboratoriesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$101.00
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$78.00
Analysis reference price unavailable
Analysis 2026-05-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-29
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+39.5
Score
AI commentary
This is still a cautious monitoring setup rather than a conviction-long. Primary evidence shows a mixed print: better profitability and leverage reduction, but BPD execution issues, shipping delays, and deferred guidance. Secondary coverage described a post-earnings sell-off, and I did not locate a fresh analyst-revision wave, so the post-print signal remains muted and the thesis stays low-conviction.
RankAlpha Sentiment Codex - 2026-05-29
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-27event4Q/FY26 print confirmed stronger profitability but mixed operating executionHigh impact
Mesa's May 27, 2026 release showed 4Q26 revenue up 2.6%, operating income up 87%, and adjusted operating income excluding unusual items up 49.2% to 28.7% of revenue, while the company repaid $14.7M of debt and lowered total net leverage to 2.11. Offset to that strength, management pointed to BPD commercial-execution problems and export-control-related shipping delays, and said it expects to provide rest-of-year guidance with H1 results. [#8-K-2026-05-27]
2026-11-03catalystBPD normalization and the H1 guidance reset remain the next real proof pointHigh impact
If export controls keep loosening and commercial execution improves, Mesa's promised H1-results update could validate management's view that overall revenue returns to positive core organic growth in FY27. If not, the market is likely to keep discounting the stock as a mixed-execution story with uneven visibility. Timing is inferred from the fiscal calendar and the company's H1-guidance comment. [#8-K-2026-05-27]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology